Alan Prem Kumar
Postgraduate:
Main Appointment:
Joint Appointments:
Research Fields:
Research Areas:
Research Fields:
- STEMM – Science, Technology, Engineering, Mathematics, Medical Sciences
Research Keywords:
- Drug Development
- Novel Breast Cancer Drivers
- DNA Damage Response
- Breast Cancer Resistance
- Biomarkers Of Drug Response
Current Appointments:
Brief Description of Research:
The Lyn kinase plays pivotal roles in many cellular processes – such as cell adhesion, invasion, and proliferation. Its aberrant activation contributes to various oncogenic pathways in cancer. Recently, our group has identified Lyn kinase to be a critical target in triple negative breast cancer (TNBC) and has developed a series of novel small molecule drug candidates against it. Based on our extensive in vitro and in vivo experimental findings, the therapeutic inhibition of Lyn kinase induces apoptosis and reverses the EMT properties in TNBC. Moreover, from our more recent studies, we have discovered potential immunomodulatory properties of Lyn kinase in breast cancer that warrants further investigation. Hence, in this project, the candidate would be given opportunities to characterize the novel immunomodulatory properties of Lyn kinase in TNBC (including its tumor microenvironment) and explore the potential clinical values of targeting this novel functional effect using various animal models and use of our in-house Lyn kinase-specific inhibitor.
Total Number of Publications:
Five Representative Publications:
(1). Sim WJ, Iyengar PV, Lama D, Lui SKL, Ng HC, Haviv-Shapira L, Domany E, Kappei D, Tan TZ, Saie A, Jaynes PW, Verma CS, Kumar AP, Rouanne M, Ha HK, Radulescu C, Ten Dijke P, Eichhorn PJA, Thiery JP. c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression. Nat Commun. 2019 Sep 25;10(1):4349. (IF:11.880). (2). Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA, Alharbi SA, Sethi G*, Kumar AP*, Kunnumakkara AB*. NGAL is Downregulated in Oral Squamous Cell Carcinoma and Leads to Increased Survival, Proliferation, Migration and Chemoresistance. Cancers (Basel). 2018 Jul 10;10(7). pii: E228. doi: 10.3390/cancers10070228. *co-senior authors (IF=6.162). (3). Cai W, Chen ZX, Rane G, Singh SS, Choo Z, Tan TZ, Wang C, Yuan Y, Arfuso F, Yap CT, Pongor L, Yang H, Sethi G, Benoukraf T, Tergaonkar V, Kumar AP. Wanted DEAD/H or Alive: Helicases winding up in cancers. J Natl Cancer Inst. 2017 Jan 25;109(6). (IF=12.6). (4) Loo SY, Hirpara J, Pandey V, Tan TZ, Yap CT, Lobie PE, Thiery JP, Goh BC, Pervaiz S*, Clement MV*, Kumar AP*. MnSOD Expression Regulates the Switch between an Epithelial to a Mesenchymal-like Phenotype in Breast Carcinoma. Antioxid Redox Signal 2016 Aug 20;25(6):283-99. *co-senior authors (IF=7.1). (5). Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, Chan M, Dharmarajan AM, Lee AS, Lobie PE, Yap CT*, Kumar AP*. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 2016 May;91(2):409-28*co-senior authors (IF=10.73). (6). Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP*, Tergaonkar V*. DEAD-box Helicase DP103 Defines the Metastatic Potential of Human Breast Cancers. J Clin Invest. 2014 Sep 2;124(9):3807-24. *co-senior authors (IF= 13.765). (7). Kumar AP, Loo SY, Shin SW, Tuan ZT, Eng CB, Singh R, Putti TC, Ong CW, Salto-Tellez M, Goh BC, Park JI, Thiery JP, Pervaiz S, Clement MV. Targeting MnSOD in Basal Breast Carcinoma using Agonists of PPARγ: a new strategy for enhancing chemosensitivity. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. (IF= 7.1). (8). Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJG, Arfuso F, Fox SA, Dharmarajan AM*, Kumar AP*. Secreted Frizzled Related Proteins: Implications in Cancers. Biochim Biophys Acta. 2014 Jan;1845(1):53-65. *co-senior authors. (IF=9.033). (9). Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Valli S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G. Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma in vivo. Clin Cancer Res. 2011 Mar 15;17(6):1425-39. (IF= 8.74). (10). Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clément MV. Repression of NHE1 Expression by PPAR{gamma} Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo. Cancer Res. 2009 Nov 15;69(22):8636-44. (IF= 8.56).
My Research Videos:
Top 5 Publications:
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
Journals Published:
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
Appointments
Education
Research Areas
- Drug Development
- Novel Breast Cancer Drivers
- DNA Damage Response
- Breast Cancer Resistance
- Biomarkers Of Drug Response
Research Description
The Lyn kinase plays pivotal roles in many cellular processes – such as cell adhesion, invasion, and proliferation. Its aberrant activation contributes to various oncogenic pathways in cancer. Recently, our group has identified Lyn kinase to be a critical target in triple negative breast cancer (TNBC) and has developed a series of novel small molecule drug candidates against it. Based on our extensive in vitro and in vivo experimental findings, the therapeutic inhibition of Lyn kinase induces apoptosis and reverses the EMT properties in TNBC. Moreover, from our more recent studies, we have discovered potential immunomodulatory properties of Lyn kinase in breast cancer that warrants further investigation. Hence, in this project, the candidate would be given opportunities to characterize the novel immunomodulatory properties of Lyn kinase in TNBC (including its tumor microenvironment) and explore the potential clinical values of targeting this novel functional effect using various animal models and use of our in-house Lyn kinase-specific inhibitor.
Research Videos
Selected Publications
(1). Sim WJ, Iyengar PV, Lama D, Lui SKL, Ng HC, Haviv-Shapira L, Domany E, Kappei D, Tan TZ, Saie A, Jaynes PW, Verma CS, Kumar AP, Rouanne M, Ha HK, Radulescu C, Ten Dijke P, Eichhorn PJA, Thiery JP. c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression. Nat Commun. 2019 Sep 25;10(1):4349. (IF:11.880). (2). Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA, Alharbi SA, Sethi G*, Kumar AP*, Kunnumakkara AB*. NGAL is Downregulated in Oral Squamous Cell Carcinoma and Leads to Increased Survival, Proliferation, Migration and Chemoresistance. Cancers (Basel). 2018 Jul 10;10(7). pii: E228. doi: 10.3390/cancers10070228. *co-senior authors (IF=6.162). (3). Cai W, Chen ZX, Rane G, Singh SS, Choo Z, Tan TZ, Wang C, Yuan Y, Arfuso F, Yap CT, Pongor L, Yang H, Sethi G, Benoukraf T, Tergaonkar V, Kumar AP. Wanted DEAD/H or Alive: Helicases winding up in cancers. J Natl Cancer Inst. 2017 Jan 25;109(6). (IF=12.6). (4) Loo SY, Hirpara J, Pandey V, Tan TZ, Yap CT, Lobie PE, Thiery JP, Goh BC, Pervaiz S*, Clement MV*, Kumar AP*. MnSOD Expression Regulates the Switch between an Epithelial to a Mesenchymal-like Phenotype in Breast Carcinoma. Antioxid Redox Signal 2016 Aug 20;25(6):283-99. *co-senior authors (IF=7.1). (5). Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, Chan M, Dharmarajan AM, Lee AS, Lobie PE, Yap CT*, Kumar AP*. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 2016 May;91(2):409-28*co-senior authors (IF=10.73). (6). Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP*, Tergaonkar V*. DEAD-box Helicase DP103 Defines the Metastatic Potential of Human Breast Cancers. J Clin Invest. 2014 Sep 2;124(9):3807-24. *co-senior authors (IF= 13.765). (7). Kumar AP, Loo SY, Shin SW, Tuan ZT, Eng CB, Singh R, Putti TC, Ong CW, Salto-Tellez M, Goh BC, Park JI, Thiery JP, Pervaiz S, Clement MV. Targeting MnSOD in Basal Breast Carcinoma using Agonists of PPARγ: a new strategy for enhancing chemosensitivity. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. (IF= 7.1). (8). Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJG, Arfuso F, Fox SA, Dharmarajan AM*, Kumar AP*. Secreted Frizzled Related Proteins: Implications in Cancers. Biochim Biophys Acta. 2014 Jan;1845(1):53-65. *co-senior authors. (IF=9.033). (9). Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Valli S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G. Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma in vivo. Clin Cancer Res. 2011 Mar 15;17(6):1425-39. (IF= 8.74). (10). Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clément MV. Repression of NHE1 Expression by PPAR{gamma} Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo. Cancer Res. 2009 Nov 15;69(22):8636-44. (IF= 8.56).